

The Royal Marsden NHS Foundation Trust
Drug & Therapeutic Committee minutes
26th November 2019

Present: Consultant Breast and AOS (deputy chair)
Drug Resource Manager (secretary)
Consultant AOS
Consultant GI
Consultant Pharmacist
Clinical Oncology Consultant
DDU fellow (Medical Oncology)
Consultant in Medical Oncology - Sarcoma
Consultant Haemato-oncology
Consultant Microbiologist

In attendance:

1. Minutes of the September meeting

- a. Minutes – approved.

2. Conflict of Interest

No conflicts raised.

3. NICE Guidance update

1. TA604 Idelalisib in refractory follicular lymphoma.
2. TA611 Rucaparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian or peritoneal ca.
3. TA610 Pentosan polysulfate sodium for treating bladder pain syndrome.
4. National Guidance; Cannabis based medicinal products. To be reviewed by pharmacy and summarized at the December meeting.
Relevant clinical leads made aware of the guidance.

4. One off drug use requests

1. Trametinib in recurrent low grade serous ovarian ca.
2. Lorlatinib in ALK+ve adenocarcinoma NSCLC.
3. Lorlatinib in ALK+ve adenocarcinoma NSCLC.
4. Eculizumab in transplant associated thrombotic microangiopathy.
5. Nivolumab in advanced mRCC (sarcomatoid histology).
6. Belantamab in relapsed refractory Multiple Myeloma.
7. Sativex in case refractory to standard therapy (muscle spasm/central pain).
8. Intranasal diamorphine to avoid the requirement of a PCA in the homecare setting.
9. LOXO-292 in metastatic medullary thyroid ca.
10. Ameluz (x3) in actinic keratosis treatment – full proposal to December meeting.
11. Gemcitabine & brentuximab in relapsed Hodgkins Lymphoma salvage treatment.
12. Pembrolizumab in squamous cell carcinoma of the bladder.
13. Apalutamide non metastatic castrate resistant prostate ca.

14. Gemtuzumab in relapsed AML.
 15. Alectenib in (via CUP) mCRPC with ALK oncogene mutation
- All requests approved.

5. Morphine gel for pain relief. Presented by Tissue Viability Nurse

Proposed for use as in two indications:

1. moist desquamation from radiotherapy (analgesia).
2. malignant fungating wounds

Action:

Service Evaluation to be undertaken and findings reported back to committed.

6. Ripretinib (via compassionate supply). Presented by Sarcoma Unit

Proposed for use as treatment in Gastrointestinal Stromal Tumour (GIST) as 4th line therapy, or 3rd line if patient unable to tolerate standard therapy in line with the compassionate supply program.

Action:

Approved.

7. Beclometasone dipropionate for check point inhibitor induced colitis. Presented by the Acute oncology Service.

Proposed for use as treatment for checkpoint inhibitor induced colitis for microscopic or collagenous colitis. Data within the ulcerative colitis setting demonstrates that modified released beclometasone is effective for microscopic colitis.

Action:

Approved.

8. Sodium thiosulfate in high risk hepatoblastoma & HD cisplatin. Presented by Children & Young Persons unit.

Proposed for use for the prevention of hearing loss in patients diagnosed with high risk hepatoblastoma, due to receive high doses of cisplatin.

Action:

Approved.

9. Dabrafenib and Trametinib (via compassionate supply). Presented by Thyroid unit

Proposed for use as treatment of advanced/Metastatic Anaplastic Thyroid Cancer for which there are currently no standard of care treatment options, in line with the compassionate supply program.

Action:

Approved, trust SACT guideline to be amended to include.

10. PGD: PGD (x4). Presented by Nursing.

- Magnesium sulphate.
- Hartmann's solution.
- Lidocaine.
- Urokinase.

Action:

Approved.

11. Lorazepam for laryngo-pharyngeal dyspasia. Presented by GI unit.

Proposed for use in oxaliplatin induced laryngo-pharyngeal dysaesthesia during the oxaliplatin infusion or after completing chemotherapy.

Action:

Approved. Audit to be carried out and findings presented at a future meeting. PGD to be developed.

12. AOB

Date of the Next Meeting:

Friday 20th of December (pm), 15:00 – 17:00

Minutes Approved	DTC chair: Friday 20 th December 2019
------------------	--

Date of next meeting 20 th December 2019.
--